Literature DB >> 19352616

[Significance of phosphodiesterase isoenzymes in the control of human detrusor smooth muscle function. An immunohistochemical and functional study].

S Uckert1, K Sigl, E S Waldkirch, P Sandner, E Ulbrich, M Oelke, C G Stief, M A Kuczyk.   

Abstract

OBJECTIVES: The use of inhibitors of phosphodiesterase (PDE) isoenzymes 1 and 5 to treat overactive bladder has been suggested. To further evaluate the significance of PDE isoenzymes in detrusor smooth muscle relaxation, we investigated the effects of selective PDE inhibitors on the tension induced by carbachol of isolated human detrusor tissue. Using immunohistochemical methods, the expression of PDE1, PDE4, and PDE5 in human detrusor was also investigated.
MATERIAL AND METHODS: The expression of PDE1, PDE4, and PDE5 was evaluated by means of conventional immunohistochemistry (IHC). Using the organ bath technique, the effects of the PDE inhibitors vinpocetine, rolipram, sildenafil, tadalafil, and vardenafil on the tension induced by the muscarinic agonist carbachol (1 microM) were investigated.
RESULTS: The tension induced by carbachol was dose-dependently reversed by the PDE inhibitors; the maximum reversal of tension ranged from 7% (tadalafil) to 34% (vardenafil). IHC revealed that the expression of PDE isoenzymes was limited to the smooth musculature of the detrusor. While there was prominent expression of PDE4 and PDE5, immunoreactions indicating the presence of PDE1 were less abundant.
CONCLUSION: Despite the fact that inhibitors of PDE1, PDE4, and PDE5 exerted only a weak relaxant response on detrusor strips precontracted by carbachol, our findings indicate that both the cAMP and cGMP pathways might be involved in the relaxation mechanism of human detrusor smooth muscle.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19352616     DOI: 10.1007/s00120-009-1970-z

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  22 in total

Review 1.  The pharmacological treatment of urinary incontinence.

Authors:  K E Andersson; R Appell; L D Cardozo; C Chapple; H P Drutz; A E Finkbeiner; F Haab; R Vela Navarrete
Journal:  BJU Int       Date:  1999-12       Impact factor: 5.588

2.  [Guidelines for German urologists on diagnosis of benign prostate syndrome].

Authors:  R Berges; K Dreikorn; K Höfner; U Jonas; K U Laval; S Madersbacher; M C Michel; R Muschter; M Oelke; L Pientka; C Tschuschke; U Tunn; K Schalkhäuser; B Göckel-Beining; A Heidenreich; H Rübben; K Schalkhäuser; W Thon; J Thüroff; W Weidner
Journal:  Urologe A       Date:  2003-03-12       Impact factor: 0.639

3.  Heme oxygenase and NO-synthase in the human prostate--relation to adrenergic, cholinergic and peptide-containing nerves.

Authors:  P Hedlund; P Ekström; B Larsson; P Alm; K E Andersson
Journal:  J Auton Nerv Syst       Date:  1997-04-14

4.  Expression of neuronal nitric oxide synthase (nNOS) and nitric-oxide-induced changes in cGMP in the urothelial layer of the guinea pig bladder.

Authors:  J I Gillespie; M Markerink-van Ittersum; J de Vente
Journal:  Cell Tissue Res       Date:  2005-06-17       Impact factor: 5.249

5.  Characterization and localization of nitric oxide synthase in the human prostate.

Authors:  A L Burnett; M P Maguire; S L Chamness; D D Ricker; M Takeda; H Lepor; T S Chang
Journal:  Urology       Date:  1995-03       Impact factor: 2.649

6.  Distribution of nitric oxide synthase implies a regulation of circulation, smooth muscle tone, and secretory function in the human prostate by nitric oxide.

Authors:  W Bloch; T Klotz; C Loch; G Schmidt; U Engelmann; K Addicks
Journal:  Prostate       Date:  1997-09-15       Impact factor: 4.104

7.  Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Authors:  Kevin T McVary; Claus G Roehrborn; Jed C Kaminetsky; Stephen M Auerbach; Barton Wachs; Jay M Young; Anne Esler; Gregory D Sides; Bela S Denes
Journal:  J Urol       Date:  2007-04       Impact factor: 7.450

8.  Characterization and functional role of androgen-dependent PDE5 activity in the bladder.

Authors:  Sandra Filippi; Annamaria Morelli; Peter Sandner; Benedetta Fibbi; Rosa Mancina; Mirca Marini; Mauro Gacci; Linda Vignozzi; Gabriella Barbara Vannelli; Marco Carini; Gianni Forti; Mario Maggi
Journal:  Endocrinology       Date:  2006-11-30       Impact factor: 4.736

9.  In vitro functional responses of isolated normal human prostatic tissue to compounds interacting with the cyclic guanosine monophosphate pathway.

Authors:  Giorgi Kedia; Stefan Uckert; Friedemann Scheller; Teimuraz Chigogidze; Lauri Managadze; Udo Jonas; Michael C Truss
Journal:  Urology       Date:  2006-05-06       Impact factor: 2.649

10.  Effects of nitric oxide on human and canine prostates.

Authors:  M Takeda; R Tang; E Shapiro; A L Burnett; H Lepor
Journal:  Urology       Date:  1995-03       Impact factor: 2.649

View more
  9 in total

1.  Constitutively active phosphodiesterase activity regulates urinary bladder smooth muscle function: critical role of KCa1.1 channel.

Authors:  Wenkuan Xin; Qiuping Cheng; Rupal P Soder; Eric S Rovner; Georgi V Petkov
Journal:  Am J Physiol Renal Physiol       Date:  2012-08-15

Review 2.  Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction.

Authors:  Stefan Uckert; Matthias Oelke
Journal:  Br J Clin Pharmacol       Date:  2011-08       Impact factor: 4.335

3.  Phosphodiesterase1 inhibitor "Vinpocetine" ameliorates the inflammation, apoptosis and oxidative stress induced by cyclophosphamide in urinary bladder: an experimental study.

Authors:  Rehab Sabri Abdelrahman; Eman Mohamad El Nashar; Mansour Abdullah Alghamdi; Khulood Mohammed Al-Khater; Reham Ismail Taha
Journal:  Int Urol Nephrol       Date:  2022-07-11       Impact factor: 2.266

4.  Expression of Phosphodiesterase (PDE) Isoenzymes in the Human Male and Female Urethra.

Authors:  Harrina E Rahardjo; Stefan Ückert; Andreas Bannowsky; Markus A Kuczyk; George T Kedia
Journal:  Res Rep Urol       Date:  2021-03-19

Review 5.  The role of phosphodiesterases in bladder pathophysiology.

Authors:  Mohammad S Rahnama'i; Stefan Ückert; Ramona Hohnen; Gommert A van Koeveringe
Journal:  Nat Rev Urol       Date:  2013-05-14       Impact factor: 14.432

6.  Phosphodiesterase type 5 (PDE5) is co-localized with key proteins of the nitric oxide/cyclic GMP signaling in the human prostate.

Authors:  Stefan Ückert; Eginhard S Waldkirch; Axel S Merseburger; Markus A Kuczyk; Matthias Oelke; Petter Hedlund
Journal:  World J Urol       Date:  2013-03-09       Impact factor: 4.226

7.  PDE5-Is for the Treatment of Concomitant ED and LUTS/BPH.

Authors:  M Gacci; A Sebastianelli; M Salvi; L Vignozzi; G Corona; K T McVary; S A Kaplan; M Oelke; M Maggi; M Carini
Journal:  Curr Bladder Dysfunct Rep       Date:  2013-06

8.  Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.

Authors:  Smita Pattanaik; Ravimohan S Mavuduru; Arabind Panda; Joseph L Mathew; Mayank M Agarwal; Eu Chang Hwang; Jennifer A Lyon; Shrawan K Singh; Arup K Mandal
Journal:  Cochrane Database Syst Rev       Date:  2018-11-16

9.  Phosphodiesterase type 4 inhibition enhances nitric oxide- and hydrogen sulfide-mediated bladder neck inhibitory neurotransmission.

Authors:  Ángel Agis-Torres; Paz Recio; María Elvira López-Oliva; María Pilar Martínez; María Victoria Barahona; Sara Benedito; Salvador Bustamante; Miguel Ángel Jiménez-Cidre; Albino García-Sacristán; Dolores Prieto; Vítor S Fernandes; Medardo Hernández
Journal:  Sci Rep       Date:  2018-03-16       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.